drugset / Trial / NCT02173951

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

NCT02173951

Phase 2/3 Unknown 64 enrolled Ain Shams University
RandomizedCrossoverOpen-labelTreatment

Summary

A prospective randomized study on Safety, Tolerability and Efficacy of oral Low dose DFP (50 mg/kg/day) in minimally transfused B-TM after 5 transfusions when SF reaches 500 ng/m and with either appearance of LPI \> 0.2 or TSAT reaches 50% compared with non treatment arm. So the aim of this study: 1. To determine the time as well as amount of transfused iron ( calculated in mg iron/kg ) which lead to Serum ferritin reaches 500 ng /ml and LPI appearance \>0.2 as well as TSAT reaches 50 % . 2. Tolerability and safety of early low dose DFP 50mg/kg and effectiveness to postpone or prevent SF from reaching 1000 ng/ml or LPI \>0.6 or TSAT \>70% in comparison to patients not starting chelation therapy 3. Determine adverse events whether drug or non drug related

Timeline

Start
2014-07
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Deferiprone Small molecule 50 mg/kg Oral
Comparator Deferiprone Small molecule 75 mg/kg Oral